Trillium Therapeutics Profit Margin

Trillium Therapeutics (TRIL) currently reports a profit margin of 151351.16% as of September 2021. That compares with -89801.67% in the prior-year period — up 268.5% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Trillium Therapeutics's profit margin history and peer comparisons.

Trillium Therapeutics's profit margin increased from -89801.67% to 151351.16% — a 268.5% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Trillium Therapeutics's profit margin of 151351.16% is higher than the Healthcare sector average of 14.34%. That is roughly 1054995.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Trillium Therapeutics's current 151351.16% should be judged against Healthcare norms (sector average: 14.34%) and against TRIL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 151351.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Trillium Therapeutics, and consider following TRIL for alerts when major investors trade the stock.